16.02.21|CTechThe Israeli company is developing and commercializing cures for blood cancers and serious hematologic diseases
28.10.18|Lilach BaumerThe Israel-based biotech company offered its shares at $8, below its previous intention of $13 to $15 per share
18.10.18|Lilach BaumerThe Jerusalem-based biotech company filed for a $69 million initial public offering in September but disclosed no pricing terms
30.09.18|Dror ReichThe Jerusalem-based company develops cellular and immune therapies. Its lead product is a universal bone marrow transplant solution
21.11.17|Lilach BaumerThe Novartis-backed company is developing a universal bone marrow transplant solution for patients unable to find a donor